RU99100325A - POLYMORPHIC MODIFICATIONS OF HONETEPSIL OF HYDROCHLORIDE AND METHOD FOR THEIR PRODUCTION - Google Patents
POLYMORPHIC MODIFICATIONS OF HONETEPSIL OF HYDROCHLORIDE AND METHOD FOR THEIR PRODUCTIONInfo
- Publication number
- RU99100325A RU99100325A RU99100325/04A RU99100325A RU99100325A RU 99100325 A RU99100325 A RU 99100325A RU 99100325/04 A RU99100325/04 A RU 99100325/04A RU 99100325 A RU99100325 A RU 99100325A RU 99100325 A RU99100325 A RU 99100325A
- Authority
- RU
- Russia
- Prior art keywords
- donepezil hydrochloride
- polymorphic modification
- iii
- hydrochloride according
- donepezil
- Prior art date
Links
- 238000006011 modification reaction Methods 0.000 title claims 54
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 title claims 34
- 230000004048 modification Effects 0.000 claims 53
- 229960003135 Donepezil hydrochloride Drugs 0.000 claims 51
- XWAIAVWHZJNZQQ-UHFFFAOYSA-N donepezil hydrochloride Chemical compound [H+].[Cl-].O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 XWAIAVWHZJNZQQ-UHFFFAOYSA-N 0.000 claims 51
- IOLCXVTUBQKXJR-UHFFFAOYSA-M Potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 claims 22
- ADEBPBSSDYVVLD-UHFFFAOYSA-N Donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 claims 11
- 238000002441 X-ray diffraction Methods 0.000 claims 11
- 238000010521 absorption reaction Methods 0.000 claims 11
- 229960003530 donepezil Drugs 0.000 claims 11
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims 11
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims 11
- 239000000843 powder Substances 0.000 claims 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 10
- 238000001228 spectrum Methods 0.000 claims 10
- 239000002904 solvent Substances 0.000 claims 8
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims 6
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 6
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 4
- IHMQOBPGHZFGLC-UHFFFAOYSA-N 5,6-dimethoxy-2,3-dihydroinden-1-one Chemical compound C1=C(OC)C(OC)=CC2=C1C(=O)CC2 IHMQOBPGHZFGLC-UHFFFAOYSA-N 0.000 claims 2
- VHOVSQVSAAQANU-UHFFFAOYSA-M Mepiquat chloride Chemical compound [Cl-].C[N+]1(C)CCCCC1 VHOVSQVSAAQANU-UHFFFAOYSA-M 0.000 claims 2
- 238000002425 crystallisation Methods 0.000 claims 2
- 230000005712 crystallization Effects 0.000 claims 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims 2
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N 2-Pentanone Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 239000012456 homogeneous solution Substances 0.000 claims 1
- 238000001556 precipitation Methods 0.000 claims 1
- 230000003595 spectral Effects 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Images
Claims (39)
(1) полиморфная модификация (I),
пики на картине дифракции рентгеновских лучей порошкового образца: представлены в графической части,
длины волн (см-1) поглощения в инфракрасной области спектра в бромиде калия:
463, 502, 563, 589, 604, 701, 750, 759, 799, 860, 922, 947, 972, 1012, 1038, 1104, 1120, 1128, 1175, 1192, 1218, 1250, 1267, 1316, 1368, 1410, 1433, 1440, 1455, 1472, 1502, 1591, 1606, 1644, 1684, 2412, 2530, 2559, 2595, 2620, 2717, 2840, 2858, 2924, 3004, 3074, 3259, 3373, 3547, 3589 см-1.1. Donepezil hydrochloride, 1-benzyl-4 - [(5,6-dimethoxy-1-indanon) -2-yl] methylpiperidine hydrochloride, in the form of polymorphic modifications selected from the group consisting of (I), (II), (III) and (IV), each of the polymorphic modifications can be determined from the peaks in the X-ray diffraction pattern of the powder sample, with the diffraction angles shown below with the intensity shown below, expressed as I / I o , and from the infrared absorption peaks shown below spectral regions in potassium bromide, expressed as inverse centimeters:
(1) polymorphic modification (I),
the peaks in the x-ray diffraction pattern of the powder sample: presented in the graphic part,
wavelengths (cm -1 ) absorption in the infrared region of the spectrum in potassium bromide:
463, 502, 563, 589, 604, 701, 750, 759, 799, 860, 922, 947, 972, 1012, 1038, 1104, 1120, 1128, 1175, 1192, 1218, 1250, 1267, 1316, 1368, 1410, 1433, 1440, 1455, 1472, 1502, 1591, 1606, 1644, 1684, 2412, 2530, 2559, 2595, 2620, 2717, 2840, 2858, 2924, 3004, 3074, 3259, 3373, 3547, 3589 cm -1 .
пики на картине дифракции рентгеновских лучей порошкового образца: представлены в графической части,
длины волн (см-1) поглощения в инфракрасной области спектра в бромиде калия:
699, 748, 762, 845, 947, 1009, 1035, 1067, 1103, 1118, 1129, 1174, 1193, 1206, 1222, 1247, 1267, 1317, 1365, 1422, 1436, 1456, 1465, 1502, 1592, 1607, 1688, 2412, 2489, 2627, 2846, 2868, 2913, 2928, 3435, см-1
(3) полиморфная модификация (III)
пики на картине дифракции рентгеновских лучей порошкового образца: представлены в графической части,
длины волн (см-1) поглощения в инфракрасной области спектра в бромиде калия:
559, 641, 648, 702, 749, 765, 786, 807, 851, 872, 927, 949, 966, 975, 982, 1007, 1034, 1071, 1080, 1111, 1119, 1131, 1177, 1190, 1205, 1217, 1230, 1250, 1265, 1292, 1313, 1367, 1389, 1420, 1438, 1453, 1461, 1470, 1500, 1589, 1605, 1697, 2407, 2419, 2461, 2624, 2641, 2651, 2667, 2837, 2848, 2873, 2924, 2954, 2961, 2993, 3007, 3377, 3433 см-1.2) polymorphic modification (II)
the peaks in the x-ray diffraction pattern of the powder sample: presented in the graphic part,
wavelengths (cm -1 ) absorption in the infrared region of the spectrum in potassium bromide:
699, 748, 762, 845, 947, 1009, 1035, 1067, 1103, 1118, 1129, 1174, 1193, 1206, 1222, 1247, 1267, 1317, 1365, 1422, 1436, 1456, 1465, 1502, 1592, 1607, 1688, 2412, 2489, 2627, 2846, 2868, 2913, 2928, 3435, cm -1
(3) polymorphic modification (III)
the peaks in the x-ray diffraction pattern of the powder sample: presented in the graphic part,
wavelengths (cm -1 ) absorption in the infrared region of the spectrum in potassium bromide:
559, 641, 648, 702, 749, 765, 786, 807, 851, 872, 927, 949, 966, 975, 982, 1007, 1034, 1071, 1080, 1111, 1119, 1131, 1177, 1190, 1205, 1217, 1230, 1250, 1265, 1292, 1313, 1367, 1389, 1420, 1438, 1453, 1461, 1470, 1500, 1589, 1605, 1697, 2407, 2419, 2461, 2624, 2641, 2651, 2667, 2837, 2848, 2873, 2924, 2954, 2961, 2993, 3007, 3377, 3433 cm -1 .
пики на картине дифракции рентгеновских лучей порошкового образца: представлены в графической части,
длины волн (см-1) поглощения в инфракрасной области спектра в бромиде калия:
401, 431, 459, 467, 490, 506, 518, 561, 586, 606, 631, 651, 709, 758, 766, 857, 944, 1009, 1041, 1106, 1119, 1132, 1213, 1225, 1265, 1304, 1318, 1429, 1458, 1470, 1500, 1589, 1605, 1630, 1647, 1683, 2562, 2577, 2608, 2634, 2689, 2717, 2836, 2924, 2949, 2989, 3007, 3032, 3061, 3322, 3376, 3422 см-1.(4) polymorphic modification (IV),
the peaks in the x-ray diffraction pattern of the powder sample: presented in the graphic part,
wavelengths (cm -1 ) absorption in the infrared region of the spectrum in potassium bromide:
401, 431, 459, 467, 490, 506, 518, 561, 586, 606, 631, 651, 709, 758, 766, 857, 944, 1009, 1041, 1106, 1119, 1132, 1213, 1225, 1265, 1304, 1318, 1429, 1458, 1470, 1500, 1589, 1605, 1630, 1647, 1683, 2562, 2577, 2608, 2634, 2689, 2717, 2836, 2924, 2949, 2989, 3007, 3032, 3061, 3322, 3376, 3422 cm -1 .
(1) полиморфная модификация (I)
пики на картине дифракции рентгеновских лучей порошкового образца: представлены в графической части,
длины волн (см-1) поглощения в инфракрасной области спектра в бромиде калия: 562.7, 603.2, 700.4, 749.6, 798.1, 859.2, 896.0, 921.3, 946.3, 971.8, 1038.0, 1119.3, 1216.9, 1266.0, 1315.4, 1367.7, 1454.1, 1501.5, 1537.8, 1555.9, 1590.7, 1643.7, 1681.9, 2350.9, 2534.0, 2922.1, 3381.8, 3585.2 см-1.13. Donepezil hydrochloride, 1-benzyl-4 - [(5,6-dimethoxy-1-indanon) -2-yl] methylpiperidine hydrochloride, in the form of polymorphic modifications selected from the group consisting of (I), (II), (III), (IV) and (V), each of the polymorphic modifications can be determined from the peaks in the X-ray diffraction pattern of the powder sample, with the diffraction angles shown below with the intensity shown below, expressed as I / I o , and as shown below absorption peaks in the infrared region of the spectrum in potassium bromide, expressed as inverse centimeters:
(1) polymorphic modification (I)
the peaks in the x-ray diffraction pattern of the powder sample: presented in the graphic part,
wavelengths (cm -1 ) of absorption in the infrared region of the spectrum in potassium bromide: 562.7, 603.2, 700.4, 749.6, 798.1, 859.2, 896.0, 921.3, 946.3, 971.8, 1038.0, 1119.3, 1216.9, 1266.0, 1315.4, 1367.7, 1454.1, 1501.5, 1537.8, 1555.9, 1590.7, 1643.7, 1681.9, 2350.9, 2534.0, 2922.1, 3381.8, 3585.2 cm -1 .
пики на картине дифракции рентгеновских лучей порошкового образца: представлены в графической части,
длины волн (см-1) поглощения в инфракрасной области спектра в бромиде калия:
560.1, 698.9, 749.1, 846.2, 947.6, 1036.1, 1119.3, 1222.7, 1266.4, 1318.7, 1364.1, 1458.3, 1500.9, 1522.3, 1534.0, 1542.6, 1560.2, 1570.3, 1592.0, 1637.0, 1647.9, 1654.4, 1689.5, 1718.3, 1734.7, 1751.7, 1773.9, 1793.8, 1830.7, 1846.0, 1870.1, 2345.1, 2489.9, 2927.9, 3448.1 см-1.(2) polymorphic modification (II),
the peaks in the x-ray diffraction pattern of the powder sample: presented in the graphic part,
wavelengths (cm -1 ) absorption in the infrared region of the spectrum in potassium bromide:
560.1, 698.9, 749.1, 846.2, 947.6, 1036.1, 1119.3, 1222.7, 1266.4, 1318.7, 1364.1, 1458.3, 1500.9, 1522.3, 1534.0, 1542.6, 1560.2, 1570.3, 1592.0, 1637.0, 1647.9, 1654.4, 1689.5, 1718.3, 1734.7, 1751.7, 1773.9, 1793.8, 1830.7, 1846.0, 1870.1, 2345.1, 2489.9, 2927.9, 3448.1 cm -1 .
пики на картине дифракции рентгеновских лучей порошкового образца: представлены в графической части,
длины волн (см-1) поглощения в инфракрасной области спектра в бромиде калия:
558.3, 641.1, 702.4, 748.5, 765.0, 786.1, 807.3, 850.8, 872.0, 926.8, 974.9, 1034.1, 1071.5, 1111.6, 1190.1, 1216.6, 1265.4, 1291.9, 1312.9, 1364.4, 1420,2, 1438.1, 1458.8, 1499.1, 1522.2, 1542.6, 1560.1, 1570.2, 1589.1, 1638.8, 1647.8, 1654.3, 1697.3, 1718.1, 1734.5, 1751.4, 1773.7, 1793.5, 1845.8, 2345.3, 2461.6, 2924.2, 3447,9 см-1.3) polymorphic modification (III),
the peaks in the x-ray diffraction pattern of the powder sample: presented in the graphic part,
wavelengths (cm -1 ) absorption in the infrared region of the spectrum in potassium bromide:
558.3, 641.1, 702.4, 748.5, 765.0, 786.1, 807.3, 850.8, 872.0, 926.8, 974.9, 1034.1, 1071.5, 1111.6, 1190.1, 1216.6, 1265.4, 1291.9, 1312.9, 1364.4, 1420.2, 1412.1, 1464.4, 1229.9, 1312.9, 1364.4, 1420.2, 1412.1, 1364.4, 1420.2 1522.2, 1542.6, 1560.1, 1570.2, 1589.1, 1638.8, 1647.8, 1654.3, 1697.3, 1718.1, 1734.5, 1751.4, 1773.7, 1793.5, 1845.8, 2345.3, 2461.6, 2924.2, 3447.9 cm -1 .
пики на картине дифракции рентгеновских лучей порошкового образца: представлены в графической части,
длины волн (см-1) поглощения в инфракрасной области спектра в бромиде калия:
561.5, 709.0, 766.2, 786.3, 804.9, 857.0, 944.3, 979.3, 1041.5, 1118.7, 1264.6, 1318.7, 1364.1, 1458.1, 1499.2, 1542.5, 1560.1, 1588.1, 1636.6, 1647.8, 1654.3, 1684.3, 1718.2, 1734.4, 1751.4, 1773.7, 1793.5, 1830.5, 1845.8, 1870.1, 2344.8, 2369.3, 2719.2, 2922.9, 3324.0 см-1.4) polymorphic modification (IV),
the peaks in the x-ray diffraction pattern of the powder sample: presented in the graphic part,
wavelengths (cm -1 ) absorption in the infrared region of the spectrum in potassium bromide:
561.5, 709.0, 766.2, 786.3, 804.9, 857.0, 944.3, 979.3, 1041.5, 1118.7, 1264.6, 1318.7, 1364.1, 1458.1, 1499.2, 1542.5, 1560.1, 1588.1, 1636.6, 1647.8, 1654.3, 1684.3, 1718.2, 1734.4, 1751.4, 1773.7, 1793.5, 1830.5, 1845.8, 1870.1, 2344.8, 2369.3, 2719.2, 2922.9, 3324.0 cm -1 .
длины волн (см-1) поглощения в инфракрасной области спектра в бромиде калия:
506.5, 559.7, 594.4, 698.0, 740.8, 805.1, 861.9, 948.5, 972.1, 1039.9, 1120.8, 1220.7, 1264.8, 1314.6, 1364.1, 1458.0, 1499.5, 1542.5, 1560.2, 1592.1, 1692.9, 2500.1, 2924.2, 2998.9, 3422.1 см-1.5) polymorphic modification (V) of the peaks in the X-ray diffraction pattern of the powder sample are presented in the graphic part,
wavelengths (cm -1 ) absorption in the infrared region of the spectrum in potassium bromide:
506.5; 559.7; 594.4; 698.0; 740.8; 805.1; 861.9; 948.5; 972.1; 1039.9; 1120.8; 1220.7; 1264.8; 1314.6; 1364.1; 1458.0; 1499.5; 1542.5; 1560.2; 1592.1; 1692.9; -1 .
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP14629396 | 1996-06-07 | ||
JP8/146293 | 1996-06-07 | ||
WOPCT/JP96/03881 | 1996-12-27 | ||
PCT/JP1996/003881 WO1997046526A1 (en) | 1996-06-07 | 1996-12-27 | Stable polymorphs of donepezil (1-benzyl-4-[(5,6-dimethoxy-1-indanon)-2-yl]methylpiperidine) hydrochloride and process for production |
US08/774,802 US6140321A (en) | 1996-06-07 | 1996-12-30 | Polymorphs of donepezil hydrochloride and process for production |
US08/774,802 | 1996-12-30 |
Publications (2)
Publication Number | Publication Date |
---|---|
RU99100325A true RU99100325A (en) | 2000-12-10 |
RU2190603C2 RU2190603C2 (en) | 2002-10-10 |
Family
ID=27307991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU99100325/04A RU2190603C2 (en) | 1996-06-07 | 1997-06-06 | Polymorphic modifications of donepezil hydrochloride, methods of their preparing and method of treatment of disease accompanying with acetylcholinesterase activity |
Country Status (12)
Country | Link |
---|---|
EP (2) | EP1019374B1 (en) |
AU (1) | AU731282B2 (en) |
CA (1) | CA2252806C (en) |
DK (1) | DK1019374T3 (en) |
ES (1) | ES2188946T3 (en) |
HK (1) | HK1020952A1 (en) |
NO (1) | NO321267B1 (en) |
NZ (1) | NZ333197A (en) |
RU (1) | RU2190603C2 (en) |
SI (1) | SI9720038B (en) |
SK (1) | SK285312B6 (en) |
WO (1) | WO1997046527A1 (en) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0971713B1 (en) * | 1997-03-03 | 2003-05-28 | Eisai Co., Ltd. | Use of cholinesterase inhibitors to treat disorders of attention |
GB9716879D0 (en) * | 1997-08-08 | 1997-10-15 | Shire Int Licensing Bv | Treatment of attention deficit disorders |
ES2218869T3 (en) * | 1997-12-05 | 2004-11-16 | Eisai Co., Ltd. | DONEPEZIL POLYMORPHIC CRYSTALS AND A PROCESS FOR THE PRODUCTION OF SUCH CRYSTALS. |
US6193993B1 (en) | 1998-03-03 | 2001-02-27 | Eisai Co., Ltd. | Suppository containing an antidementia medicament |
US6288108B1 (en) | 1998-06-16 | 2001-09-11 | Eli Lilly And Company | Methods for increasing levels of acetylcholine |
CA2335295A1 (en) * | 1998-06-16 | 1999-12-23 | Eli Lilly And Company | Methods for increasing levels of acetylcholine |
CN1305343A (en) * | 1998-06-16 | 2001-07-25 | 伊莱利利公司 | Methods for increasing levels of acetylchotine |
DE60124730T2 (en) | 2000-03-03 | 2007-10-04 | Eisai R&D Management Co., Ltd. | NEW METHODS USING CHOLINESTERASEINHIBITORS |
SI21223A (en) * | 2002-06-19 | 2003-12-31 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Pharmaceutical composition with stabilised amorphous donepezil,chloride |
IL150509A (en) | 2002-07-01 | 2007-07-04 | Joseph Kaspi | Pharmaceutical compositions containing donepezil hydrocholoride |
AU2003287433A1 (en) * | 2002-11-01 | 2004-06-07 | Oregon Health And Science University | Treatment of hyperkinetic movement disorder with donepezil |
US20050288330A1 (en) * | 2004-06-29 | 2005-12-29 | Avinash Naidu | Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) |
WO2006011154A1 (en) * | 2004-07-28 | 2006-02-02 | Usv Limited | A novel polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) and a process for producing thereof |
US7186842B2 (en) | 2003-02-12 | 2007-03-06 | Usv, Ltd. | Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof |
WO2004092137A1 (en) * | 2003-04-16 | 2004-10-28 | Hetero Drugs Limited | Novel crystalline forms of donepezil hydrochloride |
WO2006015338A2 (en) * | 2004-07-30 | 2006-02-09 | Dr. Reddy's Laboratories Ltd. | Crystalline form of donepezil hydrochloride |
RS51271B (en) | 2004-10-19 | 2010-12-31 | Krka Tovarna Zdravil D.D. | Solid pharmaceutical composition comprising donepezil hydrochloride |
WO2006090263A1 (en) * | 2005-02-28 | 2006-08-31 | Ranbaxy Laboratories Limited | Stable form i donepezil hydrochloride and process for its preparation and use in pharmaceutical compositions |
EP1858848A1 (en) * | 2005-03-17 | 2007-11-28 | Synthon B.V. | Process for making crystalline donepezil hydrochloride monohydrate |
WO2006111983A2 (en) * | 2005-04-21 | 2006-10-26 | Jubilant Organosys Limited | NOVEL POLYMORPHIC FORM OF (l-BENZYL-4-[(5,6-DIMETHOXY-l- INDANONE)-2-YL]METHYL PIPERIDINE HYDROCHLORIDE AND PROCESS FOR PREPARING THE SAME |
GB0515803D0 (en) * | 2005-07-30 | 2005-09-07 | Pliva Hrvatska D O O | Intermediate compounds |
HU227474B1 (en) * | 2005-12-20 | 2011-07-28 | Richter Gedeon Nyrt | Process for industrial scale production of high purity donepezil hydrochloride polymorph i. |
DE602007003024D1 (en) | 2006-06-27 | 2009-12-10 | Sandoz Ag | NEW PROCESS FOR SALT PRODUCTION |
US8247563B2 (en) | 2006-12-11 | 2012-08-21 | Reviva Pharmaceuticals, Inc. | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors |
DE102007037932A1 (en) | 2007-08-11 | 2009-02-12 | Alfred E. Tiefenbacher Gmbh & Co.Kg | Donepezil hydrochloride in amorphous form containing tablet |
JP5426554B2 (en) * | 2007-09-28 | 2014-02-26 | 天津和美生物技▲術▼有限公司 | Donepezil salt, polymorph thereof, production method thereof, application method and composition |
JP5562337B2 (en) * | 2008-12-17 | 2014-07-30 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | Donepezil polymorph crystal and process for producing the same |
DE102010010998A1 (en) | 2010-03-10 | 2011-09-15 | Stada Arzneimittel Ag | A solid pharmaceutical composition comprising donepezil hydrochloride of crystalline polymorphic form I |
WO2011151359A1 (en) | 2010-06-02 | 2011-12-08 | Noscira, S.A. | Combined treatment with a cholinesterase inhibitor and a thiadiazolidinedione derivative |
EP2502620A1 (en) | 2011-03-24 | 2012-09-26 | Krka Tovarna Zdravil, D.D., Novo Mesto | Solid pharmaceutical composition comprising donepezil |
CN110393440B (en) * | 2019-06-28 | 2021-08-13 | 顾美红 | Instant heating type water boiling machine |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI95572C (en) * | 1987-06-22 | 1996-02-26 | Eisai Co Ltd | Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt |
-
1997
- 1997-06-06 AU AU29792/97A patent/AU731282B2/en not_active Expired
- 1997-06-06 EP EP97924337A patent/EP1019374B1/en not_active Expired - Lifetime
- 1997-06-06 WO PCT/JP1997/001932 patent/WO1997046527A1/en not_active Application Discontinuation
- 1997-06-06 SI SI9720038A patent/SI9720038B/en active Search and Examination
- 1997-06-06 SK SK1676-98A patent/SK285312B6/en not_active IP Right Cessation
- 1997-06-06 CA CA002252806A patent/CA2252806C/en not_active Expired - Lifetime
- 1997-06-06 NZ NZ333197A patent/NZ333197A/en not_active IP Right Cessation
- 1997-06-06 DK DK97924337T patent/DK1019374T3/en active
- 1997-06-06 RU RU99100325/04A patent/RU2190603C2/en active
- 1997-06-06 EP EP02005248A patent/EP1211243B1/en not_active Expired - Lifetime
- 1997-06-06 ES ES97924337T patent/ES2188946T3/en not_active Expired - Lifetime
-
1998
- 1998-12-07 NO NO19985721A patent/NO321267B1/en not_active IP Right Cessation
-
1999
- 1999-12-24 HK HK99106107A patent/HK1020952A1/en not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU99100325A (en) | POLYMORPHIC MODIFICATIONS OF HONETEPSIL OF HYDROCHLORIDE AND METHOD FOR THEIR PRODUCTION | |
SI9720038B (en) | Polymorphs of donepezil hydrochloride and process for production | |
RU2000107108A (en) | POLYMORPHIC FORMS 2- (3-Cyan-4-isobutyloxyphenyl) -4-methyl-5-thiazolecarboxylic acid and methods for their preparation | |
US7186842B2 (en) | Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof | |
RU2006138705A (en) | METHOD FOR PRODUCING AMLODIPINE ENANTIOMER OF HIGH OPTICAL PURITY | |
KR20060090245A (en) | 1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl]-methyl piperidine oxalate (donepezil oxalate) and its polymorphs | |
CN111574686B (en) | Star-shaped multi-response shape memory polyurethane composite material and preparation method thereof | |
CN104163785A (en) | A series of asymmetric squarine micromolecules containing indoline derivative structure, and application thereof | |
CN109134875A (en) | L-menthol is the preparation of the chiral covalent organic framework material of chiral source | |
CN107417794A (en) | A kind of photochromic fibre element and preparation method thereof | |
US20050288330A1 (en) | Process for producing a polymorphic form of (1-Benzyl-4-[(5,6-dimethoxy-1-indanone)-2-yl] methyl piperidine hydrochloride (donepezil hydrochloride) | |
Saeva et al. | Intramolecular photochemical rearrangement via an in-cage cation-radical/radical pair of an anthrylsulfonium salt derivative | |
CN1102412A (en) | Dihydro-porphin Eb-ether derivant and its synthetic method | |
Roberts et al. | Reversible insertion of CO2 into the Re H bond of photogenerated [ReH (Ph2PCH2CH2PPH2) 2] | |
CN115947683A (en) | Synthesis method of tetrahydroquinoline and derivatives thereof | |
CN110204738B (en) | Covalent organic framework material based on 1,3, 5-tri (4-aldehyde pyridyl) triazine and preparation method thereof | |
White et al. | Synthesis of the lichen metabolite (+)-bourgeanic acid and conformational analysis of its dilactone | |
Halin et al. | Sedum alkaloids—VII: Structure and synthesis of (+)-4-hydroxysedamine and (+)-4-hydroxyallosedamine | |
CN113774407A (en) | Synthetic method of graphdiyne | |
CN113200957B (en) | Acid/alkali dye co-sensitization system and preparation method and application thereof | |
CN115572289A (en) | Synthesis method of tesofensine | |
Wang et al. | Three bilindione isomers: synthesis, characterization and reactivity of biliverdin analogs | |
CN215269780U (en) | Wild pepper breeding is with seedling timing solar protection devices | |
CN216699894U (en) | Photovoltaic power generation equipment of angularly adjustable | |
CN218736157U (en) | Stem of noble dendrobium planting frame cultivated in a pot |